Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Gynecology | Infections | AIDS | Pediatrics | Pharmacy | Journal

Back to Journal Articles

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

Last Updated: April 25, 2018.

For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir compared with zidovudine, lamivudine, and ritonavir-boosted lopinavir or tenofovir, emtricitabine with ritonavir-boosted atazanavir, according to a study published in the April 26 issue of the New England Journal of Medicine.

WEDNESDAY, April 25, 2018 (HealthDay News) -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) or TDF-FTC with ritonavir-boosted atazanavir (ATV/r), according to a study published in the April 26 issue of the New England Journal of Medicine.

Kathryn Rough, Sc.D., from Harvard Medical School in Boston, and colleagues compared the risks of adverse birth outcomes among infants with in utero exposure to the three regimens, using data from two U.S.-based cohort studies.

The researchers identified 4,646 birth outcomes. Overall, 2.8 percent of infants or fetuses were exposed to TDF-FTC-LPV/r as the initial antiretroviral therapy regimen during gestation. This is in contrast with 11.6 exposed to TDF-FTC-ATV/r and 20.5 percent exposed to ZDV-3TC-LPV/r. Women receiving TDF-FTC-LPV/r had a similar risk of preterm birth (risk ratio, 0.90; 95 percent confidence interval [CI], 0.60 to 1.33) and low birth weight (risk ratio, 1.13; 95 percent CI, 0.78 to 1.64) compared with women receiving ZDV-3TC-LPV/r. Women receiving TDF-FTC-LPV/r had a similar or slightly higher risk of preterm birth (risk ratio, 1.14; 95 percent CI, 0.75 to 1.72) and low birth weight (risk ratio, 1.45; 95 percent CI, 0.96 to 2.17) compared to women receiving TDF-FTC-ATV/r.

"The risk of adverse birth outcomes was not higher with TDF-FTC-LPV/r than with ZDV-3TC-LPV/r or TDF-FTC-ATV/r among HIV-infected women and their infants in the United States," the authors write.

Abstract/Full Text (subscription or payment may be required)


Previous: Fetal Inflammation May Play Role in Preterm Labor Next: People With Opioid Use Disorder Have High Suicide Rate

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: